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GSK3βRespiratory complexes are believed to play a role in the function of the mitochondrial permeability transition
pore (PTP), whose dysregulation affects the process of cell death and is involved in a variety of diseases, in-
cluding cancer and degenerative disorders. We investigated here the PTP in cells devoid of mitochondrial
DNA (ρ0 cells), which lack respiration and constitute a model for the analysis of mitochondrial involvement
in several pathological conditions. We observed that mitochondria of ρ0 cells maintain a membrane potential
and that this is readily dissipated after displacement of hexokinase (HK) II from the mitochondrial surface by
treatment with either the drug clotrimazole or with a cell-permeant HK II peptide, or by placing ρ0 cells in a
medium without serum and glucose. The PTP inhibitor cyclosporin A (CsA) could decrease the mitochondrial
depolarization induced by either HK II displacement or by nutrient depletion. We also found that a fraction of
the kinases ERK1/2 and GSK3α/β is located in the mitochondrial matrix of ρ0 cells, and that glucose and
serum deprivation caused concomitant ERK1/2 inhibition and GSK3α/β activation with the ensuing phos-
phorylation of cyclophilin D, the mitochondrial target of CsA. GSK3α/β inhibition with indirubin-3′-oxime
decreased PTP-induced cell death in ρ0 cells following nutrient ablation. These ﬁndings indicate that ρ0
cells are equipped with a functioning PTP, whose regulatory mechanisms are similar to those observed in
cancer cells, and suggest that escape from PTP opening is a survival factor in this model of mitochondrial dis-
eases. This article is part of a Special Issue entitled: 17th European Bioenergetics Conference (EBEC 2012).
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The creation of cells depleted of mitochondrial DNA (mtDNA),
termed ρ0 cells [1,2], has been a major advance in the study and un-
derstanding of mtDNA diseases. The availability of ρ0 cells allowed
their repopulation with different mitochondrial genomes, and thus
provided an essential tool to deﬁne key pathogenic parameters such
as the degree of heteroplasmy and threshold levels of mutant mtDNA
[3,4]. ρ0 cells represent an extreme case of mitochondrial dysfunction
that has also attracted considerable interest in the ﬁelds of bioenerget-
ics and cell death [5–18], in particular about the intrinsic pathway to
apoptosis that is triggered by release of mitochondrial apoptogenicΔψm, mitochondrial membrane
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l rights reserved.proteins [19] and about the effector mechanisms of necrosis caused by
bioenergetic failure [20].
One candidate mechanism for the irreversible commitment to cell
death is the mitochondrial permeability transition pore (PTP), an inner
membrane cyclosporin (Cs) A-sensitive, high-conductance channel
whose opening causes mitochondrial depolarization and a variety of ef-
fects that depend on the PTP open time [21]. Whereas short open times
may take part in physiological Ca2+ signalling by providing mitochon-
dria with a fast Ca2+ release channel [22–26], longer openings lead to
rearrangement of the cristae and to matrix swelling and eventually
prompt outer membrane rupture followed by release of cytochrome c
andof other proapoptotic proteins (such asAIF, Smac/DIABLOand endo-
nuclease G) for which there is no selective release pathway in the outer
membrane [27].
Despite the crucial importance of PTP in cell biology and in the path-
ogenesis of a number of diseases [28], its molecular composition re-
mains an unsolved riddle. The activity of RC complexes and of ATP
synthase can inﬂuence the PTP, as ROS generated as a respiratory by-
product can elicit pore openings [29]. We have demonstrated that
the PTP modulator cyclophilin D (CyP-D) binds and inhibits the ATP
synthase [30] and that the activity of RC complex I contributes to setting
the threshold voltage for PTP opening [31], providing molecular and
conceptual bases for the existence of a functional interplay between
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opening plays a pathogenic role in two models of mitochondrial dis-
eases endowed with inactivation of RC complex I, i.e. HL180 cybrids
harboring two missense mutations causative of Leber Hereditary Optic
Neuropathy in the mtDNA ND6 gene [32,33], and the cell line XTC.UC1
(derived from a thyroid oncocytoma [34]) that bears a disruptive frame-
shift mutation in the mtDNA ND1 gene [35]. Nonetheless, whether
the PTP is involved in other mtDNA disease models is not known,
and a formal deﬁnition of the role played by RC complexes in PTP regu-
lation and molecular composition is still lacking.
Cells devoid of mtDNA also constitute a potential model for the
study of the bioenergetics of neoplasias, where mitochondrial respi-
ration is decreased and ATP is largely provided by inducing glycolysis
and uncoupling it from oxygen availability, theWarburg effect [36–38].
Thus, ρ0 cells can be considered as possessing an extreme “Warburg
phenotype”. Furthermore, reduction of mtDNA copy number was
reported in diverse types of tumors such as stomach, colon, lung [39],
hepatocellular [40], ovarian [41] and breast carcinomas [42] and astro-
cytomas [43]; mtDNA was also reported to affect angiogenesis, inva-
siveness [44,45] and resistance to death of tumor cells [15,46]. We
and others have observed that mitochondria from tumor cells display
an increased resistance to PTP opening as a death-escaping strategy,
and this is achieved both by deploying hexokinase (HK) II on the mito-
chondrial surface, where it maintains the PTP in a closed state through
a poorly deﬁned signal transduction cascade directed to matrix compo-
nents such as CyP-D [47]; and by constitutively inducing an ERK/GSK3
signalling pathway that maintains CyP-D in a dephosphorylated state,
thus enhancing the threshold for PTP induction [48,49].
In keepingwith these data, herewe observe that in human osteosar-
coma 206 ρ0 cells the PTP is induced both by HK II detachment from
mitochondria, and by modulation of an ERK/GSK3/CyP-D transduction
axis following glucose and serum depletion.2. Materials and methods
2.1. Materials, cell cultures and growth conditions
Tetramethylrhodamine methyl ester (TMRM) was from Molecular
Probes (Eugene, OR); FITC-conjugated annexin-V was from Boehringer
Mannheim (Indianapolis, IN); indirubin-3′-oxime and CsA were from
Calbiochem (San Diego, CA); cyclosporin H (CsH) was a generous
gift of Dr. Urs Ruegg, Geneva; all other chemicals were from Sigma
(Milan, Italy). Mouse monoclonal anti GSK-3α/β, Grim19, SDHA
and UQCRC1, goat polyclonal anti calnexin, HK II and VDAC1, and rab-
bit polyclonal anti ERK2, PARP and TOM20 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA); rabbit polyclonal anti phospho-
ERK1/2 (Thr202/Tyr204) and anti phospho GSK-3α/β (Ser21/9) and
rabbit monoclonal anti caspase-3 antibodies were from Cell Signaling
(Beverly, MA); mouse monoclonal anti phospho-Ser/Thr, CyP-D and
anti prohibitin antibodies were from Qiagen, Calbiochem, and Lab Vi-
sion (Fremont, CA), respectively; rabbit polyclonal anti AIF antibody
was from Exalpha Biologicals (Shirley, MA); the mouse monoclonal
OXPHOS antibody cocktail recognizing CI (NDUFB8), CII (SDHB), CIII
(core2), CIV (COXII) and CV (α) was from Mito-Sciences (Eugene,
OR). Peptides MIASHLLAYFFTELNβA-GYGRKKRRQRRRG (TAT-HK II)
and GYGRKKRRQRRRG-βA-EEEAKNAAAKLAVEILNKEKK (TAT-Ctrl)
were synthesized by a solid phase method using an automatized pep-
tide synthesizer (model 431-A, Applied Biosystems, Foster City, CA).
The human 143B osteosarcoma and the derived 206 ρ0 cell lines
were kindly provided by Lodovica Vergani (Department of Neurosci-
ences, University of Padova, Padova, Italy). Cells were grown in high
glucose (4500 mg/l) Dulbecco's modiﬁed Eagle's medium (DMEM)
containing 10% fetal bovine serum, 4 mM L-glutamine, 110 mg/l sodi-
um pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin
in a humidiﬁed incubator at 37 °C with 5% CO2. Medium of ρ0 cellswas supplemented with 50 mg/l uridine, essential amino acids and
vitamins.
2.2. Mitochondrial membrane potential and cell death
Mitochondrial membrane potential (Δψm) was measured either by
epiﬂuorescence microscopy or by ﬂow cytometry (see below). For
epiﬂuorescence microscopy cells were seeded onto 24 mm-diameter
round glass coverslips and grown for 2 days in DMEM. Δψm was mea-
sured based on the accumulation of TMRM in the presence of CsH,
which inhibits the multidrug resistance pump but not the PTP [50,51].
Cells were incubated in bicarbonate- and phenol red-free DMEM
supplemented with 10 mM Hepes and 1.6 μM CsH and loaded with
20 nM TMRM for 30 min at 37 °C. At the end of each experiment, mito-
chondria were fully depolarized by the addition of 4 μMof the protono-
phore FCCP. Cellular ﬂuorescence images were acquired with an
Olympus IX71/IX51 inverted microscope equipped with a xenon light
source for epiﬂuorescence illumination and with a 12-bit digital cooled
CCD camera (Micromax, Princeton Instruments, Trenton, NJ). For detec-
tion ofﬂuorescence 568±25 nmbandpass excitation and 585 nm long-
pass emission ﬁlter settings were used. Images were collected every
3 min with an exposure time of 100 ms (6% illumination intensity)
using a 40×, 1.3 NA oil immersion objective (Olympus). Data were ac-
quired and analyzed using Cell R software (Olympus). Clusters of several
mitochondria were identiﬁed as regions of interest, and ﬁelds not con-
taining cells were taken as the background. Sequential digital images
were acquired every minute, and the average ﬂuorescence intensity of
all relevant regions was recorded and stored for subsequent analysis.
For FACS analysis cells were resuspended in 135 mM NaCl, 10 mM
Hepes, 5 mM CaCl2 and incubated for 15 min at 37 °C with TMRM
(20 nM) and CsH (1.6 μM) or with FITC-conjugated Annexin-V, to de-
tect mitochondrial membrane depolarization (reduced TMRM stain-
ing) or phosphatidylserine exposure on the cell surface (increased
FITC-conjugated Annexin-V staining) respectively. Changes in forward
and side light scatter were assessed at the same time to measure alter-
ations in cell dimension and granularity, respectively. Samples were
analyzed on a FACSCanto II ﬂow cytometer (Becton Dickinson, San
Diego, CA, USA). Data acquisition and analysis were performed using
FACSDiva software. Regions were designed on diagrams to evaluate
the percentage of cell subpopulations as indicated in Fig. 3.
2.3. Cell lysis, fractionation, western immunoblot analysis
Total cell extracts were prepared at 4 °C in 150 mM NaCl, 20 mM
Tris–HCl pH 7.4, 5 mM EDTA, 10% glycerol, 1% Triton X-100 in the
presence of phosphatase and protease inhibitors (Sigma). To prepare
mitochondrial extracts, cells were placed in isolation buffer (250 mM
sucrose, 10 mM Tris–HCl, 0.1 mM EGTA–Tris, pH 7.4) and homoge-
nized at 4 °C. Mitochondria were then isolated by differential centri-
fugation in mitochondrial isolation buffer. Unless otherwise stated,
mitochondria were treated with trypsin at 4 °C for 1 h at a mitochon-
dria:trypsin ratio of 35:1 (w/w). After trypsin inactivation with a pro-
tease inhibitor cocktail (Sigma), mitochondria were spun at 18,000×g
at 4 °C for 10 min. For immunoprecipitation, 4 mg of extracted pro-
teins per reaction was incubated with antibodies conjugated to pro-
tein A-Sepharose beads (Pharmacia, Pﬁzer, Cambridge, MA) at 4 °C
overnight. Negative controls were performed by incubating lysates
on beads in the absence of primary antibodies. Samples were separated
under reducing conditions on SDS-polyacrylamide gels and transferred
onto Hybond-C Extra membranes (Amersham). Primary antibodies
were incubated 16 h at 4 °C, and horseradish peroxidase-conjugated
secondary antibodies were added for 1 h at room temperature. Proteins
were visualized by enhanced chemiluminescence (Millipore). Densito-
metric analysis was performed with Quantity One software (Bio-Rad
Laboratories).
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Unless otherwise stated each experiment was repeated at least
three times. Data are presented as average±S.E. or, for clarity, as rep-
resentative experiments (see ﬁgure legends for details).3. Results
3.1. Characterization of ρ0 cells
In order to characterize the 206 ρ0 human osteosarcoma cell line,
we assessed the expression of a panel of respiratory chain (RC) sub-
units, whose assembly requires proteins encoded by mitochondrial
DNA (mtDNA) genes with the exception of RC complex II. As expected,
we found that 206 ρ0 cells were totally devoid of RC complexes I and IV,
whereas they displayed a level of nuclear-encoded RC proteins of RC II
and III and of the ATP synthase comparable to the parental 143B ρ+
cells (Fig. 1A).
We also monitored Δψm in situ by measuring cell accumulation of
TMRM. Under our loading conditions mitochondrial depolarization
corresponds to a decrease of mitochondrial ﬂuorescence, since the ac-
cumulated probe is still below the quenching threshold [52]. It shouldFig. 1. ρ0 cells display a mitochondrial membrane potential and upregulate HK II. A, immun
human osteosarcoma ρ+ cells and in 206 ρ0 cells. B, epiﬂuorescence microscopy images of ρ
the addition of 4 μM FCCP. C, immunoblot analysis of HK II expression in total cell extracts fr
HK II in ρ0 cells; the lanes refer to the cytosolic (Cyto) and to the mitochondrial fraction (M
Calnexin and Tom20 are used as loading controls in A and C; calnexin, PARP and caspase-3 a
purity of mitochondria in D; Tom20 and AIF are markers of the outer mitochondrial memb
matrix proteins.be noted that cells were also treated with CsH, which does not affect
the PTP but inhibits the multidrug resistance pump and therefore
normalizes cytosolic loading with TMRM, which is a substrate of the
pump and could therefore be extruded at rates that vary widely in
different cell types [50]. Both ρ+ and ρ0 osteosarcoma cells displayed
a punctuate pattern of TMRM labelling, which disappeared after
treatment with the uncoupler FCCP (Fig. 1B), thus conﬁrming that
TMRM accumulation in ρ0 cells is due to the existence of a Δψm.3.2. HK II detachment from mitochondria as a PTP-inducing strategy
As ρ0 cells lack oxidative phosphorylation, they must entirely rely
on glycolytic activity to generate ATP. Accordingly, we found that the
expression level of the ﬁrst enzyme of the glycolytic chain, hexoki-
nase, and in particular HK isoform II, which is upregulated in tumor
cells, was increased in 206 ρ0 cells compared to parental 143B ρ+
cells (Fig. 1C). A large fraction of HK II was located in mitochondria
(Fig. 1D), as already observed in tumor cell models [47,53]. Since un-
binding of HK II from the organelles prompts PTP opening [47], we in-
duced HK II detachment in order to assess the presence of a PTP in ρ0
cells. As a ﬁrst strategy, we used the drug clotrimazole (CTM), and
found that in ρ0 cells it both caused detachment of HK II (Fig. 2A) andoblot analysis of RC protein expression from complex V (CV) to complex I (CI) in 143B
+ and ρ0 cells loaded with 20 nM TMRM before (upper panels) and after (lower panels)
om ρ+ and ρ0 cells; D, immunoblot analysis showing a mitochondria-bound fraction of
ito) before (−) or after (+) treatment with 2 μg trypsin every 70 μg of mitochondria.
re endoplasmic reticulum, nucleus and cytosol markers, respectively, used to assess the
rane and of the intermembrane space, respectively, whereas prohibitin and CyP-D are
Fig. 2. Treatment with CTM induces detachment of HK II from mitochondria and mitochondrial depolarization in 206 human osteosarcoma ρ0 cells. A, immunoblot analysis of HK II
expression in total lysates (Tot), cytosolic (Cyto) or mitochondrial fractions (Mito) before (−) or after (+) treatment with 50 μM CTM for 1 h; the mitochondrial fraction was subjected
to trypsinization at 4 °C for 1 h at a mitochondria:trypsin ratio of 35:1 (w/w); prohibitin is used as a mitochondrial loading control. B, C, TMRM epiﬂuorescence intensity of 206 ρ0 (panel
B) and 143B ρ+ (panel C) cells; where indicated 10 μM CTM and 4 μM FCCP were added in the absence (closed symbols) or presence (panel B, open symbols) of 1.6 μM CsA.
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staining performed with epiﬂuorescencemicroscopy (Fig. 2B), whereas
it was ineffective in ρ+ cells (Fig. 2C). Notably, preincubation with CsA,
a drug that targets the PTP regulator CyP-D,markedly delayed themito-
chondrial depolarization induced by CTM (Fig. 2B). In parallel, we used
aHK II-derived peptide (TAT-HK II)made cell permeant through linking
with a hydrophobic stretch of the HIV-1 TAT protein, which displacesFig. 3. The TAT-HK II peptide induces HK II detachment from mitochondria and the ensuing
immunoblot analysis of HKII expression in cytosolic (Cyto) and mitochondrial (Mito) fractio
fraction was subjected to trypsinization at 4 °C for 1 h at a mitochondria:trypsin ratio of 35
cence intensity of 143B ρ+ (panel B) and 206 ρ0 cells (panel C) cells; where indicated 5 μM
added. D, output of multiparametric FACS analysis showing the TMRM ﬂuorescence intensity
after treatment with 1.6 μM CsA (panel b), 2.5 μM TAT-HK II peptide (panel c) or 2.5 μM TAT-HK
ﬂuorescence intensity of ρ0 cells; where indicated, 2.5 μM TAT-HK II peptide was added to naiveHK II from mitochondria with very high selectivity [47]. After having
conﬁrmed the effect of the peptide on HK II binding to mitochondria
of ρ0 cells (Fig. 3A), in keeping with the CTM data, we found that TAT-
HK IIwas unable to affectΔψm of 143B ρ+ cells (Fig. 3B), but it triggered
a rapid mitochondrial depolarization in 206 ρ0 cells (Fig. 3C–E). Again,
cell pretreatment with CsA markedly inhibited the effect of TAT-HK II
(Fig. 3D–E). Taken together, these data indicate that 206 ρ0 cells aremitochondrial depolarization and PTP opening in 206 human osteosarcoma ρ0 cells. A,
ns treated with TAT-Ctrl peptide (−) or TAT-HK II peptide (+) for 1 h; mitochondrial
:1 (w/w); prohibitin is used as a mitochondrial loading control. B,C, TMRM epiﬂuores-
TAT-HK II peptide (closed symbols) or 5 μM TAT-Ctrl peptide (open symbols) were
and forward light scattering (FSC-A) of ρ0 cells in the absence of additions (panel a) and
II peptide in cells pretreated with 1.6 μM CsA (panel d). E, kinetic FACS analysis of TMRM
cells (closed symbols) or to cells that had been treated with 1.6 μM CsA (open symbols).
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mitochondrial detachment of the HK II enzyme.
3.3. Nutrient starvation is another way to induce PTP opening in 206 ρ0
cells
We and others have recently shown that PTP opening is regulated
in tumor cell models by an ERK/GSK3/CyP-D transduction axis; in mi-
tochondria, GSK3 favors PTP opening by phosphorylating CyP-D, but a
constitutively active ERK opposes this signalling by phosphorylating
and inhibiting GSK3 [48,49]. Therefore, we tried to elicit PTP opening
by exposing 206 ρ0 cells to starvation through serum and glucose de-
pletion, thus blocking ERK and triggering this transduction pathway.
As expected, in these conditions we observed both ERK inhibition
and GSK3 activation (Fig. 4A; active ERK1/2 is Ser/Thr phosphorylated,
whereas active GSK3α/β is Ser/Thr dephosphorylated). Moreover, 206
ρ0 cells underwent a rapid mitochondrial depolarization that was sensi-
tive to CsA (Fig. 4B); remarkably, in 143B ρ+ cells a 4 hour serum and
glucose depletion was unable to induce major changes in the ERK/
GSK3 signaling axis (Fig. 4A), and these cells did not undergo any mito-
chondrial depolarization (Fig. 4B). To better assess the role played by
ERK and GSK3 in PTP opening of 206 ρ0 cells, we explored the presence
of a mitochondrial fraction of these enzymes. As reported in Fig. 4C, we
could ﬁndboth ERK1/2 andGSK3α/β in 206 ρ0mitochondria, andmod-
ulation of their activity in mitochondria following serum and glucose
depletion paralleled that observed in the whole cells; in addition, a
partial tryptic digestion of the mitochondrial fraction revealed that
both kinases are located in thematrix, as they display a pattern of tryp-
sin resistance similar to that of matrix prohibitin (Fig. 4D). In accord
with an enhancing role played on PTP opening by GSK3-dependentFig. 4. FBS/glucose depletion of 206 human osteosarcoma ρ0 cells triggers PTP opening and c
of 143B ρ+ and 206 ρ0 cells before (lanes marked 0) and after the indicated times of FBS/gluc
determined on the lack of staining with TMRM, see Fig. 3C) under basal conditions (Ctrl) or a
subcellular fractions of ρ0 cells incubated for 2 h in the presence (+) or absence (−) of FBS
total lysates (Tot), cytosolic (Cyto) or mitochondrial fractions (Mito) before (lanes marked 0
reticulum, nucleus, cytosol and mitochondrial markers are as described in Fig. 1. E, Phospho-
FBS and glucose for 2 h. Blot probing with CyP-D is shown, and IgG and input of CyP-D ar
depleted or not for 6 hours of FBS and glucose; IND is the GSK3α/β inhibitor indirubin-3′-ophosphorylation of CyP-D,we observed that CyP-D is Ser/Thr phosphor-
ylated in 206 ρ0 cells after serum and glucose starvation (Fig. 4E), and
that the GSK3 inhibitor indirubin-3′-oxime inhibited cell death in these
conditions (Fig. 4F).
Notably, when 206 ρ0 cells were depleted of serum and glucose
we could observe HK II detachment frommitochondria (Fig. 4C), sug-
gesting that these conditions might converge on a PTP-opening signal
that involves HK II partition between mitochondria and cytosol.
4. Discussion
In the present manuscript we have shown (i) that ρ0 cells can un-
dergo a CsA-sensitive permeability transition; (ii) that opening of
the PTP plays a role in cell death caused by HK II detachment frommi-
tochondria and by glucose and serum deprivation; and (iii) that ρ0
cells undergo adaptive changes that are remarkably similar to those
of highly glycolytic tumor cells such as increased expression of HK II
on the mitochondrial outer membrane and regulation of PTP opening
through GSK3-dependent Ser/Thr phosphorylation of CyP-D.
The occurrence of PTP opening in ρ0 cells is debated: two studies
could not ﬁnd protective effects of CsA on either cell death induced by
staurosporine [13] or on caspase-3 activation induced by thapsigargin
[18]. Yet, a negative result cannot rule out with certainty a role of the
PTP. Indeed, CsA desensitizes but does not block the pore [54], which
may be very prone to opening in ρ0 cells given (i) their lower Δψm
[9,11] and (ii) the voltage-dependence of the PTP [55], which in ρ0
cells may be poised very close to the resting potential. Here we demon-
strate that CsA can inhibit mitochondrial depolarization induced in ρ0
cells both by HK II detachment and by serum and glucose depletion.
These results strongly argue in favor of the existence of a PTP in cellsell death through the phosphorylation of CyP-D. A, immunoblot analysis of total lysates
ose depletion. B, FACS analysis of the number of cells with depolarized mitochondria (as
fter 1 h of FBS/glucose depletion with or without 1.6 μM CsA. C, immunoblot analysis of
/glucose. D, immunoblot analysis of the subcellular expression of ERK and GSK3α/β in
) or after treatment with 2 or 4 μg of trypsin every 70 μg of mitochondria. Endoplasmic
Ser/Thr immunoprecipitations on lysates from ρ0 cells kept in medium with or without
e reported as loading controls. F, FACS analysis of annexin V-FITC staining of ρ0 cells
xime. Mean ﬂuorescence is plotted as fold change compared to control.
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pensable for PTP induction.
The observation that ρ0 cells are more sensitive than ρ+ cells to
the PTP-inducing effects of HK II detachment could ﬁnd a reasonable
explanation within the framework of the PTP voltage-dependence
[55] and in the light of previous studies on the genesis of the Δψm in
ρ0 cells [9,11]. Although the F1F0 ATP synthase of ρ0 cells does not
pump protons it is catalytically active as an ATP hydrolase, and this
activity is essential to maintain a gradient of ATP between the cytosol
and the matrix allowing the electrogenic exchange of extramitochon-
drial ATP formatrix ADP,which generates theΔψm [9]. Sensitive isotope
distribution techniques allowed to determine the Δψm of ρ0 cells to
≈−67 mV, which is about half of that maintained by parental ρ+ cells
under the same experimental conditions [11]. This means that the rest-
ing potential of ρ0 cells is closer to the voltage threshold for PTP open-
ing, which is therefore easily activated as soon as HK II is removed
from the outer membrane. Remarkably, in ρ0 cells binding of HK II to
the outer membrane of mitochondria is upregulated and contributes
to inhibition of outer membrane permeabilization via either the Bax
pathway or the permeability transition [47,56]. Thus, increased mito-
chondrial HK II in ρ0 cells appears as a protective mechanism meant
to counteract PTP opening, which is rapidly induced when HK II is de-
tached from mitochondria with either CTM or a HK II-derived peptide.
Why should PTP opening be detrimental in mitochondria that do
not pump protons across the inner mitochondrial membrane? The
very existence of a Δψm implies that the inner membrane permeabil-
ity of ρ0 cells is low enough for charge separation to occur. It has been
calculated that mitochondria in ρ0 cells utilize≈13% of the total gly-
colytic ﬂux to maintain Δψm; and that this ﬂux is ≈18% of the maxi-
mal ATP hydrolytic capacity of mitochondria as measured after
permeabilization [11]. This means that PTP opening can increase the
mitochondrial ATP hydrolytic rate up to ﬁve fold, thus drawing an in-
creased fraction of the glycolytic ATP ﬂux and contributing to ATP
depletion.
It is becoming increasingly clear that the PTP is the terminal effector
of several signal transduction modules, including organelle-restricted
kinases and phosphatases [29]. We and others have recently shown
that signalling through mitochondrial ERK and GSK3 contributes to
the anti-apoptotic phenotype of tumor cells through PTP inhibition con-
veyed by modulation of Ser/Thr CyP-D phosphorylation [48,49]. Our
present ﬁndings of a similar regulatory pattern of CyP-D in ρ0 cells fur-
ther extend the interest in this model to understand the antiapoptotic
defence mechanisms of highly glycolytic tumor cells.Acknowledgements
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